Literature DB >> 7650187

Comparative stabilities of quantitative human immunodeficiency virus RNA in plasma from samples collected in VACUTAINER CPT, VACUTAINER PPT, and standard VACUTAINER tubes.

M Holodniy1, L Mole, B Yen-Lieberman, D Margolis, C Starkey, R Carroll, T Spahlinger, J Todd, J B Jackson.   

Abstract

This study compared the levels of human immunodeficiency virus (HIV) virion RNA in plasma from whole blood collected in VACUTAINER CPT (cell preparation tube), VACUTAINER PPT (plasma preparation tube), VACUTAINER SST (serum separation tube), and standard VACUTAINER tubes with sodium heparin, acid citrate dextrose, sodium citrate, and potassium EDTA used as anticoagulants. Quantitative plasma HIV RNA levels were measured by branched-DNA signal amplification. Blood from all tubes was either processed within 1 to 3 h after collection or stored at room temperature or at 4 degrees C for analysis at 6 to 8 and 30 h postdraw. Immediately separated plasma from sodium citrate CPT tubes held at 4 degrees C maintained better stability of HIV RNA equivalents than whole blood held at room temperature or 4 degrees C. The highest number of HIV RNA equivalents was seen with EDTA VACUTAINER tubes. HIV RNA equivalents in all types of plasma were significantly higher than in SST tubes. Although a decline in HIV RNA equivalents was seen in all collection devices after 30 h, a significantly greater decline in plasma HIV RNA equivalents occurred in acid citrate dextrose VACUTAINER tubes than in citrate CPT, PPT, and standard EDTA VACUTAINER tubes. In order to minimize the variability of quantitative HIV RNA test results, our data suggest that samples collected for a particular assay should be processed at the same time postdraw using a particular tube type throughout a given study.

Entities:  

Mesh:

Substances:

Year:  1995        PMID: 7650187      PMCID: PMC228216          DOI: 10.1128/jcm.33.6.1562-1566.1995

Source DB:  PubMed          Journal:  J Clin Microbiol        ISSN: 0095-1137            Impact factor:   5.948


  11 in total

1.  Reduction in plasma human immunodeficiency virus ribonucleic acid after dideoxynucleoside therapy as determined by the polymerase chain reaction.

Authors:  M Holodniy; D A Katzenstein; D M Israelski; T C Merigan
Journal:  J Clin Invest       Date:  1991-11       Impact factor: 14.808

2.  Effect of platelet-associated virus on assays of HIV-1 in plasma.

Authors:  T H Lee; R R Stromberg; D Henrard; M P Busch
Journal:  Science       Date:  1993-12-03       Impact factor: 47.728

3.  Direct and quantitative detection of HIV-1 RNA in human plasma with a branched DNA signal amplification assay.

Authors:  M S Urdea; J C Wilber; T Yeghiazarian; J A Todd; D G Kern; S J Fong; D Besemer; B Hoo; P J Sheridan; R Kokka
Journal:  AIDS       Date:  1993-11       Impact factor: 4.177

4.  Diurnal and short-term stability of HIV virus load as measured by gene amplification.

Authors:  M Holodniy; L Mole; M Winters; T C Merigan
Journal:  J Acquir Immune Defic Syndr (1988)       Date:  1994-04

5.  Stability of infectious HIV in clinical samples and isolation from small volumes of whole blood.

Authors:  S O'Shea; T Rostron; J E Mullen; J E Banatvala
Journal:  J Clin Pathol       Date:  1994-02       Impact factor: 3.411

6.  High levels of HIV-1 in plasma during all stages of infection determined by competitive PCR.

Authors:  M Piatak; M S Saag; L C Yang; S J Clark; J C Kappes; K C Luk; B H Hahn; G M Shaw; J D Lifson
Journal:  Science       Date:  1993-03-19       Impact factor: 47.728

7.  Infectious decay of human immunodeficiency virus type 1 in plasma.

Authors:  T Moudgil; E S Daar
Journal:  J Infect Dis       Date:  1993-01       Impact factor: 5.226

8.  Inhibition of human immunodeficiency virus gene amplification by heparin.

Authors:  M Holodniy; S Kim; D Katzenstein; M Konrad; E Groves; T C Merigan
Journal:  J Clin Microbiol       Date:  1991-04       Impact factor: 5.948

9.  Stabilities of quantitative plasma culture for human immunodeficiency virus, RNA, and p24 antigen from samples collected in VACUTAINER CPT and standard VACUTAINER tubes.

Authors:  L Mole; D Margolis; R Carroll; J Todd; M Holodniy
Journal:  J Clin Microbiol       Date:  1994-09       Impact factor: 5.948

10.  Cell-free plasma human immunodeficiency virus type 1 titer assessed by culture and immunocapture-reverse transcription-polymerase chain reaction.

Authors:  R W Coombs; D R Henrard; W F Mehaffey; J Gibson; E Eggert; T C Quinn; J Phillips
Journal:  J Clin Microbiol       Date:  1993-08       Impact factor: 5.948

View more
  27 in total

1.  Investigation of effects of acid citrate dextrose and EDTA on ability to quantitatively culture human immunodeficiency virus.

Authors:  C Jennings; J W Bremer; D J Brambilla
Journal:  J Clin Microbiol       Date:  2000-09       Impact factor: 5.948

2.  Plasma versus serum for detection of herpes simplex virus type 2-specific immunoglobulin G antibodies with a glycoprotein G2-based enzyme immunoassay.

Authors:  Thomas L Cherpes; Leslie A Meyn; Sharon L Hillier
Journal:  J Clin Microbiol       Date:  2003-06       Impact factor: 5.948

3.  Comparison of blood collected in acid-citrate-dextrose and EDTA for use in human immunodeficiency virus peripheral blood mononuclear cell cultures.

Authors:  S A Fiscus; H Chakraborty; R Shepard; M Goodman
Journal:  J Clin Microbiol       Date:  2000-02       Impact factor: 5.948

4.  Intra- and interlaboratory variabilities of results obtained with the Quantiplex human immunodeficiency virus type 1 RNA bDNA assay, version 3.0.

Authors:  J A Kellogg; P V Atria; J C Sanders; M E Eyster
Journal:  Clin Diagn Lab Immunol       Date:  2001-05

Review 5.  Determinations of levels of human immunodeficiency virus type 1 RNA in plasma: reassessment of parameters affecting assay outcome. TUBE Meeting Workshop Attendees. Technology Utilization for HIV-1 Blood Evaluation and Standardization in Pediatrics.

Authors:  J Lew; P Reichelderfer; M Fowler; J Bremer; R Carrol; S Cassol; D Chernoff; R Coombs; M Cronin; R Dickover; S Fiscus; S Herman; B Jackson; J Kornegay; A Kovacs; K McIntosh; W Meyer; N Michael; L Mofenson; J Moye; T Quinn; M Robb; M Vahey; B Weiser; T Yeghiazarian
Journal:  J Clin Microbiol       Date:  1998-06       Impact factor: 5.948

6.  Stability of human immunodeficiency virus RNA in blood specimens as measured by a commercial PCR-based assay.

Authors:  K Sebire; K McGavin; S Land; T Middleton; C Birch
Journal:  J Clin Microbiol       Date:  1998-02       Impact factor: 5.948

7.  Assessment of hepatitis B virus DNA stability in serum by the Chiron Quantiplex branched-DNA assay.

Authors:  M Krajden; L Comanor; O Rifkin; A Grigoriew; J M Minor; G F Kapke
Journal:  J Clin Microbiol       Date:  1998-02       Impact factor: 5.948

8.  Circulating transcriptome reveals markers of atherosclerosis.

Authors:  Willmar D Patino; Omar Y Mian; Ju-Gyeong Kang; Satoaki Matoba; Linda D Bartlett; Brenda Holbrook; Hugh H Trout; Louis Kozloff; Paul M Hwang
Journal:  Proc Natl Acad Sci U S A       Date:  2005-02-22       Impact factor: 11.205

9.  Performance characteristics of the TRUGENE HIV-1 Genotyping Kit and the Opengene DNA Sequencing System.

Authors:  Daniel R Kuritzkes; Robert M Grant; Paul Feorino; Marshal Griswold; Marie Hoover; Russell Young; Stephen Day; Robert M Lloyd; Caroline Reid; Gillian F Morgan; Dean L Winslow
Journal:  J Clin Microbiol       Date:  2003-04       Impact factor: 5.948

10.  Evaluation of the VACUTAINER PPT Plasma Preparation Tube for use with the Bayer VERSANT assay for quantification of human immunodeficiency virus type 1 RNA.

Authors:  Tarek Elbeik; Patricia Nassos; Patricia Kipnis; Barbara Haller; Valerie L Ng
Journal:  J Clin Microbiol       Date:  2005-08       Impact factor: 5.948

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.